Get started
Xeris Biopharma Holdings, Inc. 8.0% 15-JUL-2028Xeris Biopharma Holdings, Inc. 8.0% 15-JUL-2028Xeris Biopharma Holdings, Inc. 8.0% 15-JUL-2028

Xeris Biopharma Holdings, Inc. 8.0% 15-JUL-2028

No trades
See on Supercharts
Overview
Analysis

XERS5927663 chart


Full chart

Key terms


Outstanding amount
—
Face value
1,000.00 USD
Minimum denomination
1,000.00 USD
Coupon
8.00% (Fixed)
Coupon frequency
Semi-annual
Yield to maturity
−0.49%
Maturity date
Jul 15, 2028
Term to maturity
3 years

About Xeris Biopharma Holdings, Inc. 8.0% 15-JUL-2028


Issuer
Xeris Biopharma Holdings, Inc.
Sector
Health Technology
Industry
Biotechnology
Home page
xerispharma.com
Issue date
Oct 28, 2024
FIGI
BBG01JJXD214
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.